Contrive Datum Insights recent study on the “Global Genital Herpes Treatment Market” (By Product Type (Acyclovir, Famciclovir, Valacyclovir); By Treatment Distribution Channel (Hospital Pharmacies, General Pharmacies, Drug stores); 2019 – 2026 offers updated industry insights, growth perspective and dynamics about the competitiveness in the market.
Genital herpes is a disease which is caused by herpes simplex virus (type 1 and type 2) and its infection is profoundly found among the sexually active person. Hence, it is categorized as sexually transmitted infection or disease. Individuals infected by genital herpes undergo through painful genital sores and severity of pain is high among individuals that have suppressed immune systems The infections of genital herpes is transferred from one body to other by touching sores or sore fluids. Based on the statistics, genital herpes is commonly found among women than in men. Currently, there are no permanent cures for the infection or disease. However, usage of antiviral medication is adopted to limit or shortens the outbreaks of infections. Global genital herpes treatment market is estimated to grow at a CAGR of XX% over the forecast period (2019 – 2026).
Increase in awareness about genital herpes is likely to fortune the market growth.
Development of small blisters and sores which bleeds or ooze through itchiness around genitals attracts herpes virus within short span of days. Furthermore, these sores are often misunderstood with pimple or ingrown hair of herpes. As a result, 90 percent of individuals that have genital herpes aren’t aware of the infection. Moreover, transmission and contagiousness of genital herpes is majorly occurred through vaginal and anal route. Hence, a rise in awareness pertaining to the symptoms and identification of genital herpes is evident. For instance, in Australia, Australian Herpes Management Forum (AHMF) an organization particularly involves in herpes management and awareness programs.
Growth in genital herpes infection among individuals is contributing to the need for treatment method.
Genital herpes infection or disease is majorly found in United States. For instance, based on the statistics of U.S. Department of Health & Human Services, it is estimated that around 776000 individuals get infected by genital herpes in U.S. Furthermore, through the estimates it is witnessed that 11.9 percent of individuals having age between 14 to 49 years are infected with HSV type 2 virus. However, prevalence of herpes infection is majorly caused by HSV type 1. Thus, with the growing infection and genital herpes among individuals majorly among women has led into the demand for treatment. Based on the treatment route of administration, the genital herpes is segregated into oral, topical and injectable. However, candidate vaccines are currently in clinical trials and do not have commercial application which could protect genital herpes infection. Hence, in the present scenario, antiviral medication and daily suppressive therapy is used primarily.
Global Genital Herpes Treatment Market, Revenue (USD Million), 2019 – 2026
The competitive landscape of the global genital herpes treatment market consists of several global and regional players. Some of the players in the market include. AiCuris Anti-infective Cures GmbH, GlaxoSmithKline plc, Maruho Co.,Ltd., Mylan N.V., Novartis AG and Sandoz AG amongst others.
Genital Herpes Treatment, By Product Type, Overview, 2019 – 2026 (USD Million)
Genital Herpes Treatment, By Treatment Distribution Channel, Overview, 2019 – 2026 (USD Million)
- Hospital Pharmacies
- General Pharmacies
- Drug stores